Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kailera Therapeutics, Inc. (KLRA : NSDQ)

• Company Description    Kailera Therapeutics Inc. is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care. Kailera Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 145

• Price / Volume Information    Yesterday's Closing Price: $16.43 Daily Weekly Monthly 20 Day Moving Average: 746,246 shares Shares Outstanding: 129.64 (millions) Market Capitalization: $2,130.05 (millions) Beta: 52 Week High: $28.23 52 Week Low: $15.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.93% -12.31% 12 Week -11.43% -13.30% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 180 THIRD AVENUE 4TH FLOOR - WALTHAM,MA 02451 USA ph: 781-317-0290 fax: - investors@kailera.com http://www.kailera.com

• General Corporate Information    Officers Ronald C. Renaud - Chief Executive Officer and President John F. Milligan - Chairman Paul Burgess - Chief Operating Officer Douglas Pagan - Chief Financial Officer Frank Clyburn - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 482931102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 129.64 Most Recent Split Date: (:1) Beta: Market Capitalization: $2,130.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 99.97% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - 11.11 03/31/26 - 9.67 12/31/25 - 12.02 Quick Ratio 06/30/26 - 11.11 03/31/26 - 9.67 12/31/25 - 12.01 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 8.63 03/31/26 - -3.49 12/31/25 - - Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©